文献速递妇科

STK11基因组改变可预测宫颈癌患者临床结局

Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.
PubMed 文献 · Gynecol Oncol · 2019-11-19

该研究对2008至2018年间在日本国立癌症中心医院接受根治性切除术的154例宫颈癌患者进行基因组分析,发现PIK3CA(36%)、STK11(16%)等基因改变频率超过5%,且STK11基因组改变患者的总体生存期较STK11野生型患者更差(风险比=10.6,P=0.0079),TCGA数据集亦显示类似结果(风险比=2.46,P=0.029)。

要点

  • STK11基因组改变与宫颈癌患者总体生存期较差相关(风险比=10.6,P=0.0079)。
  • PIK3CA突变频率为36%,STK11为16%,PTEN为11%,TP53为11%,KRAS为8%。
  • HPV阳性患者占139/154(90.3%),TP53突变见于HPV阴性标本。

核心结论

  • 超过三分之一的日本宫颈癌患者存在分子靶向治疗可针对的突变。
  • 作者提出STK11基因组改变具有预后价值。

研究设计与样本

  • 研究纳入2008至2018年在日本国立癌症中心医院接受潜在根治性切除术的154例宫颈癌患者。
  • 使用Ion AmpliSeq™ Cancer Hotspot Panel v2分析基因组DNA样本,并用TaqMan assay检测PIK3CA、ERBB2、PTEN和STK11的拷贝数改变。
  • HPV阳性结果通过基因组检测和原位杂交试验确认。

主要发现

  • PIK3CA(36%)、STK11(16%)、PTEN(11%)、TP53(11%)和KRAS(8%)的基因组改变频率超过5%。
  • KRAS突变更常见于腺癌患者,而PIK3CA突变在鳞状细胞癌患者中的频率高于其他组织学类型。
  • HPV阳性结果见于139/154(90.3%)患者,TP53突变见于HPV阴性标本。
  • STK11基因组改变患者的总体生存期较STK11野生型患者更差(风险比=10.6,P=0.0079),TCGA数据集亦显示类似结果(风险比=2.46,P=0.029)。

关键数值与推荐

  • STK11基因组改变患者总体生存期较STK11野生型患者更差的风险比为10.6(P=0.0079)。
  • TCGA数据集中STK11基因组改变患者总体生存期较STK11野生型患者更差的风险比为2.46(P=0.029)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cervical cancer is the fourth most common cause of cancer-related deaths in Asian women, due to its poor prognosis. This study aimed to decipher genomic alteration profiles of a cohort of Japanese cervical cancer patients to understand why certain patients benefited from molecular targeted therapies and their prognostic significance. METHODS: During 2008-2018, 154 cervical cancer patients underwent a potentially curative resection procedure at the National Cancer Center Hospital. Genomic DNA samples were analyzed using Ion AmpliSeq™ Cancer Hotspot Panel v2. Alterations in the copy number of PIK3CA, ERBB2, PTEN, and STK11 were detected using the TaqMan assay. HPV-positive results were confirmed by genomic testing and in situ hybridization assay. RESULTS: The frequency of genomic alterations in PIK3CA (36%), STK11 (16%), PTEN (11%), TP53 (11%), and KRAS (8%) was >5%. KRAS mutations were preferentially detected in patients with adenocarcinomas, and the frequency of PIK3CA mutations in patients with squamous cell carcinomas was higher than that in patients with other histological cancer types. HPV-positive results were observed in 139/154 (90.3%) patients, and TP53 mutants were detected in HPV-negative specimens. In this study, the overall survival of patients with genomic alterations in STK11 was worse than in patients with wild-type STK11 (hazard ratio = 10.6, P = 0.0079) and TCGA dataset (hazard ratio = 2.46, P = 0.029). CONCLUSIONS: More than one-third of Japanese cervical cancer patients exhibit mutations targeted by molecular targeted therapies. We have proposed the prognostic value of STK11 genomic alterations.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hirose S, Murakami N, Takahashi K, et al. Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients. Gynecol Oncol. 2019. PMID: 31757465. doi:10.1016/j.ygyno.2019.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。